Ability to Handle SHM
Assay Design Increases Resilience to Somatic Hypermutation (SHM)
Corrects for naturally-occurring changes in MRD markers.
Somatic hypermutation (SHM) can cause clinical assays to underestimate MRD or even miss it entirely. The clonoSEQ Assay is engineered to minimize the impact of SHM on clonoSEQ MRD results.[4,5]